Volatility Shares Trust 2x Ether ETF (BATS: ETHU)

Latest news for Volatility Shares Trust 2x Ether ETF (BATS:ETHU)

The Fund is an exchange-traded fund (ETF) that seeks to achieve its investment objective by investing its assets principally in cash-settled ether futures contracts that trade only on an exchange registered with the Commodity Futures Trading Commission, which currently is the Chicago Mercantile Exchange (CME) (Ether Futures Contracts), and cash, cash-like instruments or high-quality securities that serve as collateral to the Funds investments in Ether Futures Contracts (Collateral Investments).

2x Ether ETF

Volatility Shares Trust 2x Ether ETF

ETHUP - United States Dollar

Unicharm (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UNICY#OTC">UNICY</a>) is looking for FY2025 GAAP EPS of $0.32. sees sales of $6.730 billion.

News

Guidance

UNICY

Unicharm Sees FY2025 GAAP EPS $0.32; Sees Sales $6.730B

Earnings

Iron Mountain Q4 2024 AFFO $1.24, Sales $1.581B Miss $1.601B Estimate

Needham analyst Ami Fadia reiterates Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) from Hold to Hold.

Reiteration

Analyst Ratings

BIIB

Needham Reiterates Hold on Biogento Hold

Molson Coors Sees FY25 Net Sales 'low single-digit increase versus 2024 on a constant currency basis'

B. Riley Securities analyst Randy Binner initiates coverage on Sunrise Realty Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNS#NASDAQ">SUNS</a>) with a Buy rating and announces Price Target of $15.

Price Target

Initiation

SUNS

B. Riley Securities Initiates Coverage On Sunrise Realty Trust with Buy Rating, Announces Price Target of $15

Unicharm (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UNICY#OTC">UNICY</a>) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is a 216.67 percent decrease over earnings of $0.06 per share from the same period last year. The company reported $1.75 billion in sales this quarter. This is a 3.15 percent decrease over sales of $1.81 billion the same period last year.

Unicharm Q4 EPS $(0.07), Inline, Sales $1.75B Down From $1.81B YoY

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates FibroBiologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) with a Buy and maintains $12 price target.

FBLG

HC Wainwright & Co. Reiterates Buy on FibroBiologics, Maintains $12 Price Target

On Wednesday, U.S. markets closed mixed, with the S&amp;P 500 declining as unexpectedly high inflation data heightened concerns about delayed Fed rate cuts. Nvidia and Amazon weakened, weighing on the index, while strong earnings lifted CVS and Gilead. Inflation worries also challenged Trump&#8217;s tariff plans, adding to market uncertainty.
In economic data, January&#8217;s CPI rose faster than expected, hitting 3% year-over-year and exceeding forecasts. Monthly inflation climbed 0.5%, the highest since August 2023, accelerating from December&#8217;s 0.4% increase.
Most S&amp;P 500 sectors declined, with materials, energy, and real estate stocks falling, while consumer staples and communication services outperformed and closed higher.
The Dow Jones Industrial Average was down 0.50% and closed at 44,368.56, the S&amp;P 500 closed lower by 0.27% at 6,051.97, while the Nasdaq Composite rose 0.03% to finish at 19,649.95.
Aisa Markets Today
<ul>
<li>On Wednesday, Japan&#8217;s Nikkei 225 closed higher by 1.26%, ending the session at 39,475.50, led by gains in the Steel, Mining, and Communication sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 rose 0.06% to 8,540.00, led by gains in the Metals &amp; Mining, Materials and Resources sectors.</li>
<li>India&#8217;s Nifty 50 closed lower by 0.12% at 23,016.80, and the Nifty 500 slid 0.10%, closing at 20,886.85, led by losses in the Fast-Moving Consumer Goods, Healthcare, and Technology sectors.</li>
<li>China&#8217;s Shanghai Composite declined 0.42% and closed at 3,332.48, and Shanghai Shenzhen CSI 300 went down 0.38% at 3,905.14               .</li>
<li>Hong Kong&#8217;s Hang Seng closed the session lower by 0.20% at 21,814.37.</li>
</ul>
Eurozone at 05:30 AM ET
<ul>
<li>The European STOXX 50 was up 1.22%.</li>
<li>Germany&#8217;s DAX gained 1.44%.</li>
<li>France&#8217;s CAC rose 1.28%.</li>
<li>U.K.&#8217;s FTSE 100 index traded lower by 0.68%</li>
<li>European shares hit record highs Thursday, driven by strong earnings from Nestlé and Siemens, alongside optimism over U.S.-Russia peace talks on Ukraine. Automobiles surged, while Britain&#8217;s FTSE dipped, dragged by Unilever.</li>
</ul>
Commodities at 05:30 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 1.46% at $70.33/bbl, and Brent was down 1.36% at $74.16/bbl.</li>
<li>Oil prices edged lower as potential Russia-Ukraine peace talks and rising U.S. crude inventories pressured the market. Optimism over eased supply risks outweighed inflation concerns despite recent tightening supply trends.</li>
<li>Natural Gas gained 3.39% to $3.686.</li>
<li>Gold was trading higher by 0.53% at $2,944.81, Silver was up 0.15% to $32.835, and Copper rose 0.06% to $4.7077.</li>
</ul>
U.S. Futures at 05:30 AM ET
Dow futures were up 0.04%, S&amp;P 500 futures gained 0.01%, and Nasdaq 100 futures rose 0.16%.
Forex at 05:30 AM ET
<ul>
<li>The U.S. Dollar Index fell 0.34% to 107.64, USD/JPY was down 0.36% to 153.79, and USD/AUD rose 0.18% to 1.5954.</li>
<li>The U.S. dollar weakened as hopes for a Russia-Ukraine peace deal lifted sentiment, boosting the euro and ruble. Meanwhile, Japan&#8217;s yen strengthened due to rising inflation, and the U.K. GDP unexpectedly grew.</li>
</ul>
Photo by Pavel Bobrovskiy via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Markets Mixed, Europe Hits Highs On Earnings; Oil Dips On Russia-Ukraine Peace Talks - Global Markets Today While US Slept

Needham analyst James Ricchiuti reiterates Advanced Energy Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEIS#NASDAQ">AEIS</a>) with a Buy and maintains $145 price target.

AEIS

Needham Reiterates Buy on Advanced Energy Indus, Maintains $145 Price Target

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) with a Neutral and maintains $46 price target.

ALKS

HC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $46 Price Target

Veru (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERU#NASDAQ">VERU</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 12.5 percent increase over losses of $(0.08) per share from the same period last year.

Earnings Beats

VERU

Veru Q1 Adj EPS $(0.07) Beats $(0.08) Estimate

AGIO

Agios Pharmaceuticals Q4 Sales $10.70M Beat $9.33M Estimate, Net Loss Of $96.5M Vs. $95.9M YoY, Cash Balance Of $1.5B

Vontier Corporation Sees Q1 Adjusted EPS Of $0.71 to $0.74 Vs. $0.74 Estimate; Projects Total Sales Of $715M-$730M Vs. $737.57M Estimate

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Buy and maintains $57 price target.

APLS

HC Wainwright & Co. Reiterates Buy on Apellis Pharmaceuticals, Maintains $57 Price Target

Full Year 2025
The Company expects net sales to grow between 3% to 7% compared to 2024. This expectation assumes a 130 basis point unfavorable impact from foreign currency translation.
Adjusted EBITDA margin is expected to be between 21% and 22%, which includes approximately $20 million gross profit impact from recently announced Mexico and China import tariffs net of planned mitigation actions. Non-GAAP diluted earnings per share are expected to be the range of $14.75 to $15.25. This assumes an adjusted effective tax rate of approximately 17%.
Free cash flow is expected to be at least $750 million.

ZBRA

Zebra Technologies Expects FY25 Sales Growth Of 3%-7% Vs $5.37B Est, Adj EPS Of $14.75-$15.25 Vs $15.89 Est

Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) reported quarterly earnings of $11.64 per share which beat the analyst consensus estimate of $11.46 by 1.57 percent. This is a 283.89 percent increase over losses of $(6.33) per share from the same period last year. The company reported quarterly sales of $36.50 million which beat the analyst consensus estimate of $35.13 million by 3.90 percent. This is a 36.07 percent increase over sales of $26.82 million the same period last year.

Agios Pharmaceuticals FY 2024 GAAP EPS $11.64 Beats $11.46 Estimate, Sales $36.50M Beat $35.13M Estimate

WIIM

Molson Coors shares are trading higher after better-than-expected Q4 2024 results

Vontier Corporation Sees FY25 EPS Of $3.00-$3.15 Vs. $3.13 Estimate; Projects Total Sales Of $2.97B-$3.05B Vs. $3.07B Estimate

Outlook
First Quarter 2025
The company expects net sales to grow between 8% and 11% compared to the first quarter of 2024. This expectation includes an approximately 1 point unfavorable impact from foreign currency translation.
Adjusted EBITDA margin for the first quarter of 2025 is expected to be approximately 21%, which includes approximately $7 million gross profit impact from recently announced Mexico and China import tariffs. Non-GAAP diluted earnings per share are expected to be in the range of $3.50 to $3.70.
Full Year 2025
The Company expects net sales to grow between 3% to 7% compared to 2024. This expectation assumes a 130 basis point unfavorable impact from foreign currency translation.
Adjusted EBITDA margin is expected to be between 21% and 22%, which includes approximately $20 million gross profit impact from recently announced Mexico and China import tariffs net of planned mitigation actions. Non-GAAP diluted earnings per share are expected to be the range of $14.75 to $15.25. This assumes an adjusted effective tax rate of approximately 17%.
Free cash flow is expected to be at least $750 million.

Zebra Technologies Expects Q1 Sales Growth Of 8%-11% Vs $1.27B Est, Adj EPS Of $3.50-$3.70 Vs $3.56 Est

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Solaris Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SLSR#AMEX">SLSR</a>) with a Buy and maintains $10 price target.

Comments

Volatility Shares Trust 2x Ether ETF

News

Latest news for Volatility Shares Trust 2x Ether ETF (BATS:ETHU)

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga